We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Neurology

Active Cancer Increases Both Ischemic and Bleeding Risks in Minor Stroke Patients on DAPT: Lessons from the READAPT Study

MedXY Editorial Team•Jan 7, 2026•Neurology
Dual Antiplatelet Therapyminor stroke

Highlights

1. Patients with active cancer face a 2.75-fold higher risk of recurrent ischemic stroke or vascular events within 90 days compared to patients without cancer, even when treated with dual antiplatelet therapy (DAPT).

2. The safety profile of DAPT is significantly altered in active cancer, with a 2.5-fold increase in bleeding risk, whereas patients with cancer in remission show no significant increase in bleeding compared to non-cancer controls.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Intracranial Hemorrhage Patterns and Outcomes in Minor Stroke: Insights from the TEMPO-2 TrialSecondary analysis of TEMPO-2 trial data reveals intracranial hemorrhage in minor stroke patients increases 90-day mortality risk threefold, with higher hemorrhage rates in tenecteplase-treated patients despite most bleeds being non-symptomApr 29, 2026The 42-Hour Window: Why Delaying Dual Antiplatelet Therapy Compromises Outcomes in Minor Stroke and High-Risk TIAA large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 houJan 7, 2026The 30-Day Ischemic Penalty: Why Early Aspirin Withdrawal in ACS Requires CautionA landmark analysis from the NEOMINDSET trial demonstrates that while potent P2Y12 inhibitor monotherapy reduces bleeding, it significantly increases ischemic risk in the first 30 days after PCI for acute coronary syndrome, suggesting that Jan 3, 2026Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑SparingIn low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Dec 6, 2025
Evaluating Alteplase Use in Minor Ischemic Stroke: Insights from a Nationwide Chinese RegistryA nationwide Chinese registry analysis reveals no overall benefit of intravenous alteplase in minor ischemic stroke but suggests select subgroups, especially those with disabling symptoms or higher NIHSS scores, may experience improved funcOct 29, 2025
Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA TrialThe ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.Oct 8, 2025